These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 23229370)

  • 21. Clinical value of soluble ST2 in cardiology.
    Dudek M; Kałużna-Oleksy M; Migaj J; Straburzyńska-Migaj E
    Adv Clin Exp Med; 2020 Oct; 29(10):1205-1210. PubMed ID: 33049127
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interleukin 33 and ST2 in non-ST-elevation myocardial infarction: comparison with Global Registry of Acute Coronary Events Risk Scoring and NT-proBNP.
    Dhillon OS; Narayan HK; Quinn PA; Squire IB; Davies JE; Ng LL
    Am Heart J; 2011 Jun; 161(6):1163-70. PubMed ID: 21641364
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Interleukin-33/ST2 Pathway Is Expressed in the Failing Human Heart and Associated with Pro-fibrotic Remodeling of the Myocardium.
    Tseng CCS; Huibers MMH; van Kuik J; de Weger RA; Vink A; de Jonge N
    J Cardiovasc Transl Res; 2018 Feb; 11(1):15-21. PubMed ID: 29285671
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The levels of soluble ST2 in sera and bullous fluid from patients with bullous pemphigoid.
    Wakatabi K; Komine M; Meephansan J; Matsuyama Y; Tsuda H; Tominaga S; Ohtsuki M
    Eur J Dermatol; 2012; 22(3):333-6. PubMed ID: 22494834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ST2 may not be a useful predictor for incident cardiovascular events, heart failure and mortality.
    Hughes MF; Appelbaum S; Havulinna AS; Jagodzinski A; Zeller T; Kee F; Blankenberg S; Salomaa V;
    Heart; 2014 Nov; 100(21):1715-21. PubMed ID: 25080471
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduced levels of interleukin 33 and increased levels of soluble ST2 in subjects with amyotrophic lateral sclerosis.
    Lin CY; Pfluger CM; Henderson RD; McCombe PA
    J Neuroimmunol; 2012 Aug; 249(1-2):93-5. PubMed ID: 22633272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Soluble ST2 in Heart Failure.
    McCarthy CP; Januzzi JL
    Heart Fail Clin; 2018 Jan; 14(1):41-48. PubMed ID: 29153199
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blockade of IL-33/ST2 ameliorates airway inflammation in a murine model of allergic asthma.
    Lee HY; Rhee CK; Kang JY; Byun JH; Choi JY; Kim SJ; Kim YK; Kwon SS; Lee SY
    Exp Lung Res; 2014 Mar; 40(2):66-76. PubMed ID: 24446582
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ST2 Signaling in the Tumor Microenvironment.
    Chang CP; Hu MH; Hsiao YP; Wang YC
    Adv Exp Med Biol; 2020; 1240():83-93. PubMed ID: 32060890
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The IL-33/ST2 pathway, inflammation and atherosclerosis: Trigger and target?
    Aimo A; Migliorini P; Vergaro G; Franzini M; Passino C; Maisel A; Emdin M
    Int J Cardiol; 2018 Sep; 267():188-192. PubMed ID: 29793758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Common genetic variation at the IL1RL1 locus regulates IL-33/ST2 signaling.
    Ho JE; Chen WY; Chen MH; Larson MG; McCabe EL; Cheng S; Ghorbani A; Coglianese E; Emilsson V; Johnson AD; Walter S; Franceschini N; O'Donnell CJ; ; ; Dehghan A; Lu C; Levy D; Newton-Cheh C; ; Lin H; Felix JF; Schreiter ER; Vasan RS; Januzzi JL; Lee RT; Wang TJ
    J Clin Invest; 2013 Oct; 123(10):4208-18. PubMed ID: 23999434
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modulation of IL-33/ST2 signaling as a potential new therapeutic target for cardiovascular diseases.
    Thanikachalam PV; Ramamurthy S; Mallapu P; Varma SR; Narayanan J; Abourehab MA; Kesharwani P
    Cytokine Growth Factor Rev; 2023; 71-72():94-104. PubMed ID: 37422366
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interleukin-33 and its Receptor in Pulmonary Inflammatory Diseases.
    Zhao J; Zhao Y
    Crit Rev Immunol; 2015; 35(6):451-61. PubMed ID: 27279043
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The physiologic and pathophysiologic role of stimulating growth factor ST2.].
    Dyleva YA; Gruzdeva OV; Akbasheva OE; Uchasova EG; Barbarash OL
    Klin Lab Diagn; 2017; 62(10):599-605. PubMed ID: 30821940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction.
    Shimpo M; Morrow DA; Weinberg EO; Sabatine MS; Murphy SA; Antman EM; Lee RT
    Circulation; 2004 May; 109(18):2186-90. PubMed ID: 15117853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Soluble ST2 is associated with all-cause and cardiovascular mortality in a population-based cohort: the Dallas Heart Study.
    Chen LQ; de Lemos JA; Das SR; Ayers CR; Rohatgi A
    Clin Chem; 2013 Mar; 59(3):536-46. PubMed ID: 23220272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Soluble ST2: A complex and diverse role in several diseases.
    Homsak E; Gruson D
    Clin Chim Acta; 2020 Aug; 507():75-87. PubMed ID: 32305537
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Using ST2 in cardiovascular patients: a review.
    Daniels LB; Bayes-Genis A
    Future Cardiol; 2014 Jul; 10(4):525-39. PubMed ID: 25301315
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Status of soluble ST2 levels in serum of HTLV-1 infected individuals.
    Zahedi Avval F; Shomali S; Nadri M; Boostani R; Jarahi L; Youssefi M
    Acta Microbiol Immunol Hung; 2015 Jun; 62(2):137-45. PubMed ID: 26132834
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Soluble ST2 in Patients with Carotid Artery Stenosis-Association with Plaque Morphology and Long-Term Outcome.
    Stojkovic S; Kampf S; Harkot O; Nackenhorst M; Brekalo M; Huber K; Hengstenberg C; Neumayer C; Wojta J; Demyanets S
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.